Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia
- PMID: 18460249
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia
Abstract
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous